Efficacy and Safety of Darunavir/Ritonavir Plus Etravirine Dual Regimen in Antiretroviral Therapy–Experienced Patients: A Multicenter Clinical Experience

REFERENCES

• Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolescents. Washington, DC: US Department of Health and Human Services; 2013.
   Google Scholar
• Marcotullio S, Andreoni M, Antinori A, et al. The less drugs regimens (LDRs) therapy approach in HIV-1: An Italian expert panel perspective for the long-term management of HIV-1 infection. New Microbiol. 2012;35(3):259–277.
   PubMed Web of Science ®Google Scholar
• Kozel MJ, Lupo S, DeJesus E, et al. A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naïve HIV-infected patients: SPARTAN study results. HIV Clin Trials. 2012;13(3):119–130.
   PubMed Web of Science ®Google Scholar
• Comparative Trial of maraviroc versus emtricitabine/teno-fovir both with darunavir/ritonavir in antiretroviral-naive patients infected with CCR5 tropic HIV1 (MODERN). ViiV Healthcare, Pfizer. https://clinicaltrials.gov/ct2/show/NCT01345630?term=Modern&rank=1. Accessed June 23, 2014.
   Google Scholar
• Raffi F BA, Richert L, et al. First-line RAL + DRV/r is non inferior to TDF/FTC + DRV/r. The NEAT001/ANRS143 randomised trial. Paper presented at: Conference on Ret-roviruses and Opportunistic Infections; March 3–6, 2014; Boston, Massachussets.
   Google Scholar
• Reynes J, Trinh R, Pulido F, et al. Lopinavir/ritonavir com-bined with raltegravir or tenofovir/emtricitabine in antiret-roviral-naive subjects: 96-week results of the PROGRESS study. AIDS Res Hum Retro viruses. 2013;29(2):256–265.
   PubMed Web of Science ®Google Scholar
• Cahn P, Andrade-Villanueva J, Arribas JR, et al. Dual therapy with lopinavir and ritonavir plus lamivudine ver-sus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomised, open label, non-inferiority GARDEL trial. Lancet Infect Dis. 2014;14(7):572–580.
   PubMed Web of Science ®Google Scholar
• Cordery DV, Hesse K, Amin J, Cooper DA. Raltegravir and unboosted atazanavir dual therapy in virologically sup-pressed antiretroviral treatment-experienced HIV patients. Antivir Ther. 2010;15(7):1035–1038.
   PubMed Web of Science ®Google Scholar
• Ofotokun I, Sheth AN, Sanford SE, et al. A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically sup-pressed HIV-infected patients: A pilot randomized trial to assess efficacy and safety profile: The KITE study. AIDS Res Hum Retroviruses. 2012;28(10):1196–1206.
   PubMed Web of Science ®Google Scholar
• Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: Pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009;23(17):2289–2300.
   PubMed Web of Science ®Google Scholar
• Kumar P, Currier J, Squires K. Predictors of response in GRACE (Gender,Race and Clinical Experience). Paper presented at: Proceeding of the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA ‘09); October-November 2009; Philadelphia, PA.
   Google Scholar
• Tyrer M, Swaden L, Marshall N. Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy. Paper presented at: 10th International Congress on Drug Therapy in HIV Infection; November 7–11, 2010; Glasgow, UK.
   Google Scholar
• Bernardino J, Vergas J, Tellez M. Dual therapy with darunavir/ritonavir and etravirine in clinical practice: an NRTI-sparing strategy in ART experienced patients. Paper presented at: 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 17–20, 2011; Rome, Italy.
   Google Scholar
• Ruane P, Alas B, Ryan R, Perniciaro A, Witek J. A 48-week pilot study switching suppressed patients to darunavir/rito-navir and etravirine from enfuvirtide, protease inhibitor(s), and non-nucleoside reverse transcriptase inhibitor(s). AIDS Res Hum Retro viruses. 2010;26(11):1215–1219.
   PubMed Web of Science ®Google Scholar
• Johnson VA, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2010. Top HIV Med. 2010;18(5)156–163.
   Google Scholar
• Vingerhoets J, Nijs S, Tambuyzer L, Hoogstoel A, Anderson D, Picchio G. Similar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systems. Antivir Ther. 2012;17(8)1 571–1579.
   PubMed Web of Science ®Google Scholar
• HIVdb Stanford University. Genotypic Resistance Interpre-tation Algorithm (version 7.0). http://sierra2.stanford.edu/sierra/serylet/JSierra. Accessed June 11,2014.
   Google Scholar
• Brundage MD, Pater JL, Zee B. Assessing the reliability of two toxicity scales: Implications for interpreting toxicity data. J Nat! Cancer Inst. 1993;85(14):1138–1148.
   PubMed Web of Science ®Google Scholar
• Clotet B, Bellos N, Molina JM, et al. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369(9568)1169–1178.
   Web of Science ®Google Scholar
• Scholler-GyOre M, Kakuda TN, Sekar V, et al. Pharma-cokinetics of darunavir/ritonavir and TMC125 alone and coadministered in HIV-negative volunteers. Antivir Ther. 2007;12(5):789–796.
   PubMed Web of Science ®Google Scholar
• Di Giambenedetto S, Fabbiani M, Colafigli M, et al. Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on sta-ble treatment with two nucleos(t)ide reverse transcrip-tase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study). J Antimicrob Chemother. 2013;68(6)1 364–1372.
   Web of Science ®Google Scholar
• Negredo E, Molt) J, Burger D, et al. Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretro-viral-experienced patients (NEKA study). J Acquir Immune Defic Syndr. 2005;38(1):47–52.
   PubMed Web of Science ®Google Scholar
• Allavena C, Ferré V, Brunet-Francois C, et al. Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients. J Acquir Immune Defic Syndr. 2005;39(3):300–306.
   PubMed Web of Science ®Google Scholar
• Burgos J, Crespo M, Falcó V, et al. Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-in-fected patients. J Antimicrob Chemother. 2012;67(10): 2479–2486.
   PubMed Web of Science ®Google Scholar
• Burgos J, Crespo M, Falcó V, et al. Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiret-roviral regimen. J Antimicrob Chemother. 2012;67(6): 1453–1458.
   PubMed Web of Science ®Google Scholar
• Allavena C, Mounoury O, Rodallec A, Reliquet V, Billaud E, Raffi F. Efficacy and safety of an NRTI-sparing dual regi-men of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population. HIV Clin Trials. 2009;10(5):337–340.
   PubMed Web of Science ®Google Scholar
• Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 2011;25(17):2113–2122.
   PubMed Web of Science ®Google Scholar
• Parienti JJ, Bangsberg DR, Verdon R, Gardner EM. Better adherence with once-daily antiretroviral regimens: A meta-analysis. Clin Infect Dis. 2009;48(4):484–488.
   PubMed Web of Science ®Google Scholar
• Pulido F, Pérez-Valero I, Delgado R, et al. Risk factors for loss of virological suppression in patients receiving lopinavir/ritonavir monotherapy for maintenance of HIV suppression. Antivir Ther. 2009;14(2):195–201.
   PubMed Web of Science ®Google Scholar
• Di Biagio A, Ricci E, Viscoli C, et al. The use of nucleo-side reverse transcriptase inhibitors sparing regimens in treatment-experienced HIV-1 infected patients. Curr HIV Res. 2013;11(3):179–186.
   PubMed Web of Science ®Google Scholar
• Calcagno A, Yilmaz A, Cusato J, et al. Determinants of darunavir cerebrospinal fluid concentrations: Impact of once-daily dosing and pharmacogenetics. AIDS. 2012;26(12):1529–1533.
   PubMed Web of Science ®Google Scholar
• Tiraboschi JM, Niubo J, Vila A, Perez-Pujol S, Podzam-czer D. Etravirine concentrations in CSF in HIV-infected patients. J Antimicrob Chemother. 2012;67(6): 1446–1448.
   PubMed Web of Science ®Google Scholar